Navigation Links
Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
Date:2/7/2012

SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research and collaboration agreement with an unnamed leading worldwide pharmaceutical company. The collaboration will use Prometheus' proprietary oncology diagnostic platform (CEER) to develop diagnostic arrays relating to the partner's oncology pipeline.  The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products.

Under the terms of the non-exclusive agreement, Prometheus will receive an upfront payment for the development of the first diagnostic array, additional payments for the development of each additional array, and research and development support and testing fees.

"This program represents an important addition to the expanding list of collaborations using our proprietary CEER diagnostic platform," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "We believe our technology can increase the probability of success in clinical trials and constitutes a significant step towards personalized medicine in cancer treatment, with the ultimate goal of improving the potential outcome for patients."

Prometheus' proprietary oncology diagnostic platform has the ability to measure the expression and activation of specific cancer pathways with high levels of sensitivity and specificity via tissue or blood sample. This technology has the potential to be used not only in the development process to select and evaluate the efficacy of drugs but also in the clinical setting to enable real-time molecular profiling, monitor drug effectiveness and direct the use of a growing number of targeted therapies.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., has been operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
10. Prometheus Announces Agreement to be Acquired by Nestle Health Science
11. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)...  Edwards Lifesciences Corporation (NYSE: EW ), ... disease and critical care monitoring, plans to announce its ... after the market closes on Wednesday, February 1, 2017, ... ET that day to discuss those results. ... or (201) 689-8037.  For 72 hours following the call, ...
(Date:1/17/2017)... Jan. 17, 2017  OrthoAccel ® Technologies, Inc. ... (JCO) has published "The Effect of Vibration on Molar ... by Dr. S. Jay Bowman , this prospective, ... malocclusions, AcceleDent,s SoftPulse Technology ® speeds up molar ... reducing the number of days to move the upper ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, ... the fourth Cradle to Cradle Product Design Challenge , the Cradle to ... series of six circular design challenges scheduled to run through early 2018. The challenges ...
(Date:1/17/2017)... Baltimore, MD (PRWEB) , ... January 17, 2017 , ... ... joined the firm as a Principal in its IT Advisory Services practice . ... in recent months as market demand for strategic IT guidance grows, and the practice ...
(Date:1/17/2017)... ... January 17, 2017 , ... The ... in Tyler, has announced the latest beneficiary of their thriving community involvement program. ... organization dedicated to fulfilling the dreams of terminally ill patients. Donations to this ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
(Date:1/16/2017)... ... , ... Gym Source, America’s leading retailer of premium residential and commercial fitness ... , “We are elated to be opening this new showroom,” explains Tom Richard, Chief ... clients a seamless and motivating shopping experience.” , Every fitness journey is unique, and ...
Breaking Medicine News(10 mins):